Eltrombopag ITP denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Eltrombopag in ITP

Prior authorization (PA) is a pre-approval requirement UHC imposes on certain medications before it will cover them. For eltrombopag in ITP, PA is standard because TPO-RAs are specialty drugs with significant cost and specific clinical criteria that UHC requires to be verified before dispensing. A "prior-auth-required" denial typically means the drug was dispensed or billed before the PA was obtained, the PA was submitted but denied for failure to meet criteria, or the PA was not submitted at all. The denial does not mean the drug is inappropriate — it means the approval gateway was not completed correctly.

## Why This Denial Is Appealable

If the PA was denied on clinical grounds, that determination is a coverage decision subject to appeal. Under ACA §2719, non-grandfathered plans must offer internal appeal and external review. Under ERISA §503, employer-plan members are entitled to a full-and-fair review. The internal appeal window is generally 180 days from the denial. External review must usually be requested within 4 months of a final internal denial. An expedited review (72-hour turnaround) is available when your condition is urgent. If the denial was purely administrative — the PA was simply not submitted — resubmitting a complete PA may resolve it faster than a formal appeal.

## Concrete Appeal Steps

1. Determine the denial type: Read the denial letter to confirm whether the PA was denied on clinical grounds, denied due to missing information, or simply never submitted. 2. If clinical denial: File an internal appeal with a complete clinical package addressing every unmet criterion listed in the denial letter and the UHC coverage policy. 3. If administrative or missing-information denial: Resubmit the PA with all required fields completed and supporting documentation attached. 4. Escalate to external review if internal appeal is denied and the plan is subject to external review.

## Documentation to Gather

• ITP diagnosis confirmation: hematology notes, platelet count history, and diagnostic workup establishing chronic ITP.
• Prior treatment history: a complete chronological record of all prior ITP therapies — corticosteroids, IVIG, anti-D (if applicable), rituximab, splenectomy — with dates, responses, and reasons for discontinuation.
• Bleeding risk and symptom documentation: chart notes recording hemorrhagic events, bleeding severity assessments, or functional limitations.
• Prescriber medical-necessity letter: a letter from the hematologist documenting the clinical rationale, confirming prior-therapy failure or contraindication, and explicitly stating that the patient meets the criteria in the UHC coverage policy.
• UHC PA criteria checklist: download UHC's published clinical coverage policy for TPO-RAs and complete a point-by-point checklist with chart evidence for each criterion.

## Criteria-Mapping Structure

| UHC PA Requirement | Supporting Documentation | |---|---| | Confirmed chronic ITP diagnosis | [Hematology note + date] | | Platelet count severity per policy | [Serial counts with dates from chart] | | Prior first-line therapy (per policy) tried and failed | [Therapy, start/end date, response, reason stopped] | | Additional prior therapy requirements met | [As specified in current UHC policy] | | Prescriber specialty and attestation | [Treating hematologist letter] |

The exact criteria are in the UHC clinical coverage policy for eltrombopag or TPO-RAs (request the document number from UHC Member Services) and in the FDA-approved prescribing label for eltrombopag. Your submission must answer each criterion with a specific chart fact.